معرفی
Lindsay McKay is a Senior Research Scientist/Study Director at the Nonclinical Studies Unit within the National Emerging Infectious Diseases Laboratories (NEIDL) at Boston University. She is affiliated with Boston University CAMED and the BUMC (Boston University Medical Center). Her research focuses on virology, immunology, and microbiology, with a particular emphasis on antiviral therapies, antibody engineering, and vaccine development against pathogens such as Ebola virus and SARS-CoV-2. Her work spans molecular mechanisms of viral pathogenesis, diagnostic tool design (e.g., aptasensors), and preclinical evaluation of therapeutic candidates.
Key research areas include SARS-CoV-2 variant neutralization, mRNA vaccine optimization, and the development of pan-ebolavirus antibodies. Her recent studies highlight advancements in cross-protective antibody therapies and mRNA vaccine strategies targeting emerging viral variants. She collaborates on projects involving animal models (e.g., Syrian hamsters) to assess viral pathogenesis and vaccine efficacy.
Dr. McKay’s contributions include work on antiviral compounds (e.g., BDA-410), LNP-formulated vaccines, and the structural basis of antibody evasion by SARS-CoV-2. She also investigates host-pathogen interactions, such as hepatitis C virus modulation of cellular signaling pathways.
Her team’s findings have been disseminated through peer-reviewed articles in high-impact journals, addressing topics like Omicron variant pathogenesis, T cell vaccine design, and the structural determinants of antibody resistance. She actively participates in interdisciplinary initiatives to combat emerging infectious diseases.
